|
|
|
| Expression and significance of SRSF6 in non-small cell lung cancer |
| MEI Juan-juan1 LI Gui-he2 HUANG Wei-hua3 |
1.Department of Pathology,Dongguan Changping Hospital,Guangdong Province,Dongguan 523560,China;
2.Department of Respiratory Medicine,Dongguan Changping Hospital,Guangdong Province,Dongguan 523560,China;
3.Department of B Ultrasound,Dongguan Changping Hospital,Guangdong Province,Dongguan 523560,China |
|
|
|
|
Abstract Objective To investigate the expression and significance of serine/arginine-rich splicing factor 6(SRSF6)in non-small cell lung cancer(NSCLC).Methods Seventy-five patients with NSCLC admitted to our hospital from January 2013 to January 2017 were selected as the study subjects and divided into non-small cell lung cancer(NSCLC)tissues and corresponding adjacent tissues according to the different samples,the expression of SRSF6 in non-small cell lung cancer(NSCLC)and its adjacent tissues was detected by immunohistochemical SP method,the relationship between the expression of SRSF6 and gender,age,clinical stage,distant metastasis and differentiation of NSCLC was also analyzed.Results The positive expression of SRSF6 in NSCLC tissues was (1.65±0.48)%,which was significantly higher than(0.57±0.23)%in adjacent tissues,the difference was statistically significant(P<0.05).To investigate the relationship between SRSF6 and clinical parameters of patients with NSCLC,and according to the expression intensity of SRSF6 in lung cancer tissues,SRSF6 was divided into four groups:-,+,++,+++,it was found that SRSF6 expression was not related to age and sex of patients with NSCLC,and there was no significant difference (P>0.05).There were significant differences in clinical stage,distant metastasis and differentiation,the difference was statistically significant(P<0.05).Conclusion SRSF6 is less expressed in adjacent tissues and highly expressed in NSCLC,which provides a theoretical basis for clinical diagnosis and treatment of NSCLC,and helps to provide new ideas for clinical treatment.
|
|
|
|
|
|
| [1] |
孙义长，苏书娟，王冬营，等.SRSF1基因在非小细胞肺癌中的表达及其对预后的影响[J].临床肺科杂志，2018，23（10）：1870-1873.
|
| [2] |
马育华，彭海英，王志蕙，等.非小细胞肺癌组织中DEC1mRNA、DEC2mRNA 表达及意义[J].山东医药，2016，56（12）：20-23.
|
| [3] |
张坦，王艺瞳，方翼.非小细胞肺癌靶向治疗药物的研究现状[J].中国临床药理学杂志，2017，33（11）：1054-1057.
|
| [4] |
肖邦明，祝兴旺，董理鸣，等.SRSF1和Survivin在前列腺癌组织中的表达及其与病理分级的相关性[J].中国医科大学学报，2016，45（5）：452-455.
|
| [5] |
祝兴旺，李永智，刘屹立.SRSF1和Caspase-3在膀胱尿路上皮癌中的表达及其临床意义[J].现代肿瘤医学，2017，25（3）：412-414.
|
| [6] |
马春霞，杨梦莉，李明阳，等.顺铂处理后肺癌细胞剪接因子SRSF1mRNA异构体的变化[J].贵州医科大学学报，2017，42（8）：879-884，892.
|
| [7] |
吕自兰，郭变琴，吴立翔.SRSF1在肿瘤中的研究进展[J].检验医学与临床，2016，13（9）：1278-1280.
|
| [8] |
罗志强，李俊玉，刘珺.预防性脑照射治疗局部晚期非小细胞肺癌的临床效果[J].中国当代医药，2018，25（32）：56-58.
|
| [9] |
Ishikawa T，Krzysko KA，Kowalska-Loth B，et al.Activities of Topoisomerase I in Its Complex with SRSF1[J].Biochemistry，2012，51（8）：1803-1816.
|
| [10] |
Cohen-Eliav M，Golan-Gerstl R，Siegfried Z，et al.The splicing factor SRSF6 is amplified and is an oncoprotein in lung and colon cancers[J].J Pathol，2013，229（4）：630-639.
|
| [11] |
王海妹，周学军，黄家军，等.老年喉癌组织中人乳头状瘤病毒E7及肿瘤增殖、迁移相关基因mRNA表达量的检测及临床意义[J].中国老年学杂志，2017，37（8）：1859-1862.
|
| [12] |
Jensen MA，Wilkinson JE，Krainer AR，et al.Splicing factor SRSF6 promotes hyperplasia of sensitized skin[J].Nat Struct Mol Biol，2014，21（2）：189-197.
|
| [13] |
李冬霞，张慧，蔡松旺.p21活化激酶4在非小细胞肺癌中的表达及其临床意义[J].中国病理生理杂志，2015，31（11）：1956-1960.
|
| [14] |
陈鹏，董绍安，由玉梅.非小细胞肺癌组织中MMP-9、E-cadherin 的表达变化及其意义[J].山东医药，2017，57（25）：93-95.
|
| [15] |
卓越，梁冬.Twist和血管内皮生长因子在非小细胞肺癌组织中的表达及其与临床病理特征及预后的关系[J].中国老年学杂志，2017，37（18）：4558-4560.
|
| [16] |
Brown S.The Sheffield RNAi Screening Facility（SRSF）：portfolio growth and technology development[J].Comb Chem High Throughput Screen，2014，17（4）：319-321.
|
| [17] |
Hara H，Takeda T，Yamamoto N et al.Zinc-induced modulation of SRSF6 activity alters bim splicing to promote generation of the most potent apoptotic isoform BimS[J].FEBS J，2013，280（14）：3313-3327.
|
| [18] |
谷雪梅，张昊，来茂德.结肠正常黏膜和腺癌中差异表达基因的生物信息学分析[J].浙江大学学报（医学版），2004，33（2）：95-101，124.
|
|
|
|
